ASCO 2020：11项中国研究荣膺口头报告，17项Poster报告

深受全球开放性新近冠疫情阻碍，原计划于5月底29日~6月底2日在芝加哥主办的宾夕法尼亚州临床学术委员会（ASCO）年会今年将首次以线上基本合办，这是目前为止最大规模的线上盛会。今天，大会的简述题目公布，一共103个sessions，里国一分别为11项研究工作获选口头报告，17项获选Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或希亚替尼加卡培他中洲可用HER2+前列腺癌乳腺脾癌（PHOEBE）：一项III期随机试制。

首站：前列腺癌乳腺脾癌

创作者：里国医学科学院该医院徐兵河系主任、马飞系主任，复旦大学附属该医院胡夕春系主任等

简述号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴开放性乳腺脾癌标准化疗法后卡培他中洲维持快节奏放射疗法的III期试制（SYSUCC-001）。

首站：乳腺脾癌—暂时开放性/区域/主要用途疗法

创作者：凤林大学防治里心里山王树森系主任等

简述号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用前列腺癌大脑的表型特征来预见大脑脊液里反向DNA监测的不确定开放性: 新近应用软件对抗据说对手

首站：新近应用软件消除据说关键问题

创作者：李美芹 李德兰等

简述号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对比索拉非尼作为后半期脾细胞核脾癌的二线疗法：一项解禁附加、随机、多里心II/III期试制。

首站：呼吸道脾癌—大肠食管、血栓和实无

创作者：浙江大学华西该医院毕锋系主任、里国人民解放军新华该医院秦叔逵系主任等

简述号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

里国后半期脾脾癌病征阿帕替尼双线疗法：一项随机、安慰剂解读、双盲III期研究工作

首站：呼吸道脾癌—大肠食管、血栓和实无

创作者：里国人民解放军新华该医院秦叔逵系主任、浙江大学华西该医院李秋系主任等

简述号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

后半期住院开放性卵巢脾癌二次细胞核减灭术的一项随机III期试制：SOC1 / SGOG-OV2。

研讨：妇科脾乳癌

创作者：复旦大学附属凤林该医院臧荣余系主任等

简述：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈脾癌根治开放性输卵管切除术后主要用途疗法里的序贯放放射疗法对比分开超声或同步放放射疗法（STARS研究工作）：一项随机、解读、解禁附加的III期试制。

大会：妇科脾乳癌

创作者：凤林大学防治里心黄鹤系主任、刘继红系主任等

简述号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：主要用途吉非替尼对比放射疗法可用可切除的EGFR变异的N1-N2期NSCLC-随机III期临床试制的最终总体生存分析方法。

研讨：肺脾癌—非小细胞核暂时开放性-区域/小细胞核/其他胸部

创作者：东莞市人民该医院吴一龙系主任等

简述号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR变异寡转回非小细胞核肺脾癌病征二线丝氨酸激酶衍海洋生物为首或不为首积极前线暂时开放性超声：III期解禁附加临床随机试制（SINDAS）的里期结果（NCT02893332）。

研讨：肺脾癌-非小细胞核转回

创作者：绵阳市人民该医院曾铭系主任等

简述：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序开放性死亡者-1（PD-1）的人源化IgG4化学合成为首阿昔替尼可用前列腺癌黏膜肺癌病征的Ib期研究工作的总生存期和海洋生物遥相呼应分析方法。

研讨：肺癌/皮肤脾癌

创作者：北京大学该医院郭军、盛锡楠系主任等

简述：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的可靠开放性和结果：非标准化CAR-T细胞核首次人体试制疗法住院/难治开放性T细胞核急开放性红细胞核帕金森氏症（r/r T-ALL）的可靠开放性和。大会：开发计划里的疗法技术-免疫疗法。创作者：里山王欣欣等简述：3013名片：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在后半期食管点状细胞核脾癌病征里的应用：一项随机的解禁附加II期试制（ORIENT-2）。大会：呼吸道脾癌-大肠食管脾癌、血栓脾癌和实无道脾癌创作者：徐建明系主任等简述：4511名片：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D专一开放性CAR-T细胞核对脾母细胞核瘤的根除开放性疗法大会：里枢神经系统创作者：代红久、孙斌、杨东、徐晖、李小妹、魏佳、赵旭东简述：2522名片。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在后半期错配修复缺陷病征里的应用大会：开发计划里的疗法学-免疫疗法创作者：沈琳系主任等简述：3021名片。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART疗法住院/难治开放性ACUTE红细胞核帕金森氏症/淋巴瘤的首例人体临床试制大会: 开发计划开放性疗法学-免疫疗法创作者简介：张明志，杨林等简述：3026名片: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）为首应可用后半期实体瘤病征的Ib期研究工作大会：发展开放性疗法学----原子靶向药剂和海洋生物学创作者：龚继芳，沈琳系主任等简述：3523名片：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin为首紫杉醇和nedaplatin疗法住院开放性或前列腺癌食管点状细胞核脾癌（ESCC）病征的II期研究工作。大会：呼吸道脾癌-大肠食管、血栓和实无道脾癌的研究工作创作者：里山王志强，李玉红，里山王德申，里山王凤华，任超，谭琼 里山王志强、李玉红、里山王德深、里山王凤华、任超、谭琼简述：4522名片：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.大会：呼吸道脾癌-大肠食管脾癌、血栓脾癌和实无管脾癌的双线疗法创作者：宋艳等简述：4524名片：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿液外体外环RNA方差可用初始活检时监测高等级脾癌的尿液外体外环RNA方差：一项多里心的回顾开放性研究工作大会：心脏生殖系统脾乳癌--------脾癌、睾丸脾癌和脾癌创作者简介：Liaoyuan Li等简述：5522名片。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 暂时开放性后半期宫颈脾癌并发放射疗法后的主要用途放射疗法大会: 妇科脾乳癌创作者简介： 李珉珉等简述：6031名片：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼疗法甲状腺脾开放性脾癌的相关开放性：基于ALTER01031试制的分析方法。会衹：头颈部创作者：济南市该医院娴熟系主任简述：6526名片。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄对安洛替尼疗法后病征故事情节的阻碍: ALTER01031的亚组分析方法大会：头颈部创作者：济南市该医院娴熟系主任简述：6527名片。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA分析方法预见I-IIIA期非小细胞核肺脾癌（NSCLC）病征术后住院: GASTO1035和GASTO1018的结果大会：肺脾癌-非小细胞核暂时开放性-区域开放性/小细胞核/小细胞核/其他胸科脾乳癌创作者：Si-Yu Wang等简述：9023名片：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小细胞核肺脾癌（NSCLC）里EGFR丝氨酸激酶衍海洋生物的新近型致病机制大会:肺脾癌-非小细胞核前列腺癌肺脾癌创作者简介：赵昕，金大姐，满宇，欧秋香，华宝，薛武，杨少，范敏 赵昕、金大姐、满宇、欧秋香、华宝、薛武、杨绍、范敏简述：9528名片：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试制里后半期肺癌总生存的替代终点大会：肺癌/皮肤脾癌创作者：聂润聪，袁书强，李元芳，陈英波，周志伟 聂润聪、袁书强、李元芳、陈英波、周志伟简述：10030名片：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼疗法住院或前列腺癌原发开放性恶开放性穿孔病征的II期研究工作大会： 病症创作者：唐丽娜，牛晓辉，里山陈毅，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、里山王振、蔡启庆、涂崇奇、范正福、杨瑶简述：11525名片。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 先期赞誉安罗替尼在后半期病症病征多线疗法里的可靠开放性和。大会：病症创作者：姚伟涛，里山陈家强，里山王文，里山王欣，杜新近辉，田志浩，牛晓颖 姚伟涛、里山陈家强、里山王文、里山王鑫、杜鑫辉、田志超、牛晓英简述：11526名片：414